OBJECTIVES: To compare locoregional control with alternating chemo radiation and radiation alone in patients with locally advanced head and neck carcinoma. STUDY DESIGN: A prospective randomized study. SETTING:Tertiary academic referral center. PATIENTS: 50 patients of biopsy proven locally-advanced carcinoma of head and neck. INTERVENTION: 25 patients were kept in Group I or study group (i.e. alternating chemo-radiation) and 25 patients in Group II or control group (i.e. radiation alone). In the study group, patients were given 3 cycles of chemotherapy (Cisplatin 20 mg/m([2]) and Inj. 5-FU 200mg/m([2]) from day 1-5 of each week) during weeks 1,5 and 9 alternated with radiation dose of 10Gy/week was given during weeks 2,3,4 and 6,7,8. In the control group, patients were given a total dose of 60Gy in 6 weeks. OUTCOME MEASURES: The response rate at the primary site and nodal site was better in study group as compared to control group. RESULTS: On comparing the response at the primary and nodal site together, 72% (18/25) patients of group I and 44% (11/25) patients of group II showed CR. PR was seen in 28% (7/25) and 36% (9/25) patients in group I and II respectively. No response was seen in 5/25 (20%) of patients in Group II. CONCLUSION: Our study has revealed that alternating/ sequential chemoradiation is a promising and feasible approach for patients in advanced head and neck cancer.
RCT Entities:
OBJECTIVES: To compare locoregional control with alternating chemo radiation and radiation alone in patients with locally advanced head and neck carcinoma. STUDY DESIGN: A prospective randomized study. SETTING: Tertiary academic referral center. PATIENTS: 50 patients of biopsy proven locally-advanced carcinoma of head and neck. INTERVENTION: 25 patients were kept in Group I or study group (i.e. alternating chemo-radiation) and 25 patients in Group II or control group (i.e. radiation alone). In the study group, patients were given 3 cycles of chemotherapy (Cisplatin 20 mg/m([2]) and Inj. 5-FU 200mg/m([2]) from day 1-5 of each week) during weeks 1,5 and 9 alternated with radiation dose of 10Gy/week was given during weeks 2,3,4 and 6,7,8. In the control group, patients were given a total dose of 60Gy in 6 weeks. OUTCOME MEASURES: The response rate at the primary site and nodal site was better in study group as compared to control group. RESULTS: On comparing the response at the primary and nodal site together, 72% (18/25) patients of group I and 44% (11/25) patients of group II showed CR. PR was seen in 28% (7/25) and 36% (9/25) patients in group I and II respectively. No response was seen in 5/25 (20%) of patients in Group II. CONCLUSION: Our study has revealed that alternating/ sequential chemoradiation is a promising and feasible approach for patients in advanced head and neck cancer.
Authors: M Merlano; R Corvo; G Margarino; M Benasso; R Rosso; M R Sertoli; M Cavallari; M Scala; M Guenzi; A Siragusa Journal: Cancer Date: 1991-02-15 Impact factor: 6.860
Authors: M Merlano; V Vitale; R Rosso; M Benasso; R Corvò; M Cavallari; G Sanguineti; A Bacigalupo; F Badellino; G Margarino Journal: N Engl J Med Date: 1992-10-15 Impact factor: 91.245
Authors: Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan Journal: Cochrane Database Syst Rev Date: 2021-12-20